Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis
The multiple dose portion of the Phase 1 study enrolled 11 patients with ISM who had an unsatisfactory response to antihistamine and steroid treatment. Patients were enrolled in two cohorts and received open label AK002 doses of 1 mg/kg monthly for 6 months (cohort 9) or 1 mg/kg for the first month, followed by monthly doses of 3 to 10 mg/kg for 5 additional doses (cohort 10). Symptoms were collected daily using three ISM questionnaires: Mastocytosis Questionnaire (MSQ), Mastocytosis activity and symptom severity questionnaire (MAS2), and Mastocytosis Quality of Life questionnaire (MC-QoL). Baseline scores were collected over 14 to 28 days and compared to scores at Weeks 21 to 22, two weeks after the final AK002 dose.
“AK002 produced clinically meaningful improvements in symptoms and improved quality of life measures in patients with ISM. These results are quite exciting because there are no approved treatments for patients with this difficult to treat disease,” said principal investigator of the study, Dr.
Data for the combined cohorts are presented below; more detailed results from the study will be presented at an upcoming medical conference.
|MSQ Symptom (N=8) *||Median Change from Baseline at Weeks 21 to 22|
|*The MSQ was not available for use in 3 patients|
|MAS2 Symptom (N=11)||Median Change from Baseline at Weeks 21 to 22|
|MC-QoL Domain (N=11)||Median Change from Baseline at Weeks 21 to 22|
|Social Life / Functioning||-42%|
AK002 was generally well tolerated. The most common adverse event was mild to moderate infusion-related reactions (flushing, feeling of warmth, headache, nausea, and dizziness) which occurred mostly during the first infusion.
These results are consistent with the symptom improvements reported in the single ascending dose Phase 1 ISM study. In the single dose study, 13 patients received single escalating doses of 0.0003 to 1.0 mg/kg, including three patients receiving 0.3 mg/kg and three patients receiving 1.0 mg/kg of AK002. Five out of six patients receiving 0.3 or 1.0 mg/kg reported to the study investigators that they had improvements in symptoms, including diarrhea, abdominal pain, fatigue, pruritus, difficulty concentrating and headaches.
About Indolent Systemic Mastocytosis
Indolent systemic mastocytosis (ISM) is a disorder caused by increased numbers and activation of mast cells throughout the body. The most common areas affected are the skin, gastrointestinal tract, musculoskeletal system and central nervous system. The symptoms of ISM are caused by the increased release of mast cell mediators in tissue and include pruritus, flushing, headache, cognitive impairment, fatigue, diarrhea, gastrointestinal cramps, hypotension and skin lesions, as well as an increased risk for osteoporosis and anaphylaxis, which in some cases can be life threatening. ISM affects approximately 30,000 people in
Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, AK002, targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. AK002 has completed phase 1 studies in healthy volunteers, indolent systemic mastocytosis, and a Phase 2 trial in patients with chronic urticaria. AK002 demonstrated pharmacodynamic activity in trials and, in the trials involving patients with chronic urticaria and indolent systemic mastocytosis, patients reported improvements in their symptoms. AK002 is being tested in a double-blind, placebo-controlled Phase 2 trial for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis. In addition, Allakos is conducting multiple-dose trials with AK002 in severe allergic conjunctivitis. For more information, please visit the Company's website at www.allakos.com.
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, the timing of top-line results from Allakos’ ongoing clinical trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to: Allakos’ early stages of clinical drug development; Allakos’ ability to timely complete clinical trials for, and if approved, commercialize AK002, its lead compound; Allakos’ ability to obtain required regulatory approvals for its product candidates; uncertainties related to the enrollment of patients in its clinical trials; Allakos’ ability to demonstrate sufficient safety and efficacy of its product candidates in its clinical trials; uncertainties related to the success of later-stage clinical trials, regardless of the outcomes of preclinical testing and early-stage trials; market acceptance of Allakos’ product candidates; uncertainties related to the projections of the size of patient populations suffering from the diseases
Adam Tomasi, COO, CFO email@example.com Media Contact: Denise Powelldenise@redhousecomms.com
Source: Allakos Inc.